LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
UBS Initiates ALX Oncology(ALXO.US) With Buy Rating, Announces Target Price $1.2
UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating
LifeSci Capital Reaffirms Their Hold Rating on ALX Oncology Holdings (ALXO)
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty With a Hold Rating
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Cuts Target Price to $1.5
ALX Oncology Is Maintained at Hold by Stifel
A Quick Look at Today's Ratings for ALX Oncology(ALXO.US), With a Forecast Between $1.5 to $9
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), IGM Biosciences (IGMS) and ALX Oncology Holdings (ALXO)
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)
Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $9
ALX Oncology Holdings Analyst Ratings
Jefferies Upgrades ALX Oncology(ALXO.US) to Buy Rating, Raises Target Price to $3
ALX Oncology Upgraded to Buy From Hold at Jefferies
ALX Oncology Is Maintained at Buy by UBS
A Quick Look at Today's Ratings for ALX Oncology(ALXO.US), With a Forecast Between $3 to $5
Hold Rating for ALX Oncology Amid Mixed ASPEN-06 Study Results and Financial Concerns
Stifel Nicolaus Sticks to Its Hold Rating for ALX Oncology Holdings (ALXO)
ALX Oncology Holdings Analyst Ratings